Home   >  
Protease/Metabolic Enzyme
  >  
Mitochondrial Metabolism

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Mitochondrial Metabolism

Chemical Structure Cat. No. Product Name CAS No.
MSDC 0602 Chemical Structure
 BCP33206 MSDC 0602 1133819-87-0
MSDC 0602 is an insulin sensitizer potentially for the treatment of diabetes (metabolic modulator).
EPI-743 Chemical Structure
 BCP21072 EPI-743 1213269-98-7
EPI 743 is a potent cellular oxidative stress protectant, which could be used to treat mitochondrial diseases.
Lonidamine Chemical Structure
 BCP06555 Lonidamine 50264-69-2
Lonidamine is an orally administered small molecule hexokinase inactivator with an IC50 of 0.85 mM.
Daidzin Chemical Structure
 BCP11504 Daidzin 552-66-9
Daidzin is a natural organic compound in the class of phytochemicals known as isoflavones.Daidzin has shown the potential for the treatment of alcohol dependency (antidipsotropic) based on animal models.
UK-5099 Chemical Structure
 BCP02330 UK-5099 56396-35-1
UK 5099 is an inhibitor of the mitochondrial pyruvate carrier (MPC) and plasma membrane monocarboxylate transporters (MCTs).
FCCP Chemical Structure
 BCP29558 FCCP 370-86-5
FCCP is a mitochondrial uncoupling agent, used in cancer research.
Rotenone Chemical Structure
 BCP07278 Rotenone 83-79-4
Rotenone is an inhibitor of mitochondrial electron transport at NADH:ubiquinone oxidoreductase, and is used to induce a Parkinson-like syndrome as an experimental model in rats.
Imeglimin hydrochloride Chemical Structure
 BCP11078 Imeglimin hydrochloride 775351-61-6
Imeglimin HCl is an oxidative phosphorylation blocker, inhibiting hepatic gluconeogenesis, increasing muscle glucose uptake, and restoring normal insulin secretion.
Imeglimin Chemical Structure
 BCP11085 Imeglimin 775351-65-0
Imeglimin(EMD-387008) is the first in a new tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins; It has been shown to act on the liver, muscle and pancreatic β-cells to uniquely target the key defects of type 2 diabetes.
共 9 条记录 1 / 1 页
0086-15971444841